New triple therapy shows promise for tough liver cancers
NCT ID NCT06349317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with liver cancer that has spread to the portal vein (the main blood vessel to the liver). Participants will receive radiation therapy before surgery, along with two drugs (camrelizumab and apatinib) before and after surgery. The goal is to see if this combination can prevent the cancer from coming back. About 33 adults with this specific type of liver cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mengchao Hepatobiliary Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?